Back to Journals » OncoTargets and Therapy » Volume 8

Original Research

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

       
Total article views   HTML views PDF downloads Totals
8,854 Dovepress* 7,883+ 1,814 9,697
PubMed Central* 971 463 1,434
Totals 8,854 2,277 11,131
*Since 14 May 2015
+Since July 2016

View citations on PubMed and Google Scholar